Prothena | PRTA - Operating Profit


Prothena reported $-27.21M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD -10.95M 100.03M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Immunic USD -25.73M 2.91M Sep/2024
Incyte USD 383.88M 47.43M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Prothena USD -27.21M 12.55M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xoma USD -15.64M 5.56M Sep/2024